Is Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

Bruce Jacobs Biography and Net Worth

CFO of Kymera Therapeutics

As CFO, Bruce directs financial operations and investor relations for Kymera Therapeutics. Bruce joined Kymera with more than 25 years of experience in health care financial services, investment banking and equity research. He previously was Managing Partner for Westfield Capital Management, a Boston-based equity investment firm. In addition to his core portfolio management responsibilities, he served on the firm’s Management Committee and as the Health Care Team Lead. Bruce was also a Director with Alex Brown & Sons/Deutsche Bank and part of the health care investment banking group and the equity research team. He graduated magna cum laude from the Wharton School of the University of Pennsylvania, earned a Master of Business Administration from the Harvard Business School and is a Chartered Financial Analyst. Bruce is currently a member of the Board of Directors at Boys & Girls Clubs of Boston and serves on the Board of Advisors for Life Science Cares.

What is Bruce N. Jacobs' net worth?: The estimated net worth of Bruce N. Jacobs is at least $5.79 million as of March 4th, 2024. Mr. Jacobs owns 142,351 shares of Kymera Therapeutics stock worth more than $5,787,992 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Jacobs may own. Learn More about Bruce N. Jacobs' net worth.
How do I contact Bruce N. Jacobs?: The corporate mailing address for Mr. Jacobs and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Bruce N. Jacobs' contact information.
Has Bruce N. Jacobs been buying or selling shares of Kymera Therapeutics?: Bruce N. Jacobs has not been actively trading shares of Kymera Therapeutics in the last ninety days. Most recently, Bruce N. Jacobs sold 3,934 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $41.86, for a transaction totalling $164,677.24. Following the completion of the sale, the chief financial officer now directly owns 142,351 shares of the company's stock, valued at $5,958,812.86. Learn More on Bruce N. Jacobs' trading history.
Who are Kymera Therapeutics' active insiders?: Kymera Therapeutics' insider roster includes Jeffrey Albers (Director), Bruce Booth (Director), Richard Chesworth (Insider), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Jared Gollob (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO). Learn More on Kymera Therapeutics' active insiders.
Are insiders buying or selling shares of Kymera Therapeutics?: In the last twelve months, insiders at the sold shares 16 times. They sold a total of 1,008,191 shares worth more than $40,176,324.03. The most recent insider tranaction occured on September, 17th when Director Pamela Esposito sold 13,500 shares worth more than $651,780.00. Insiders at Kymera Therapeutics own 15.8% of the company. Learn More about insider trades at Kymera Therapeutics.
Information on this page was last updated on 9/17/2024.

Bruce N. Jacobs Insider Trading History at Kymera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2024	Sell	3,934	$41.86	$164,677.24	142,351
3/2/2023	Sell	1,370	$31.00	$42,470.00	104,568
1/12/2022	Sell	15,000	$51.85	$777,750.00
12/3/2021	Sell	10,000	$53.56	$535,600.00
9/3/2021	Sell	10,000	$60.12	$601,200.00
6/3/2021	Sell	10,000	$46.87	$468,700.00
3/15/2021	Sell	8,195	$60.17	$493,093.15	1,805
3/11/2021	Sell	1,805	$60.07	$108,426.35	1,805
3/8/2021	Sell	10,000	$50.65	$506,500.00	10,000

Bruce N. Jacobs Buying and Selling Activity at Kymera Therapeutics

Kymera Therapeutics Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $40.66

$38.24

$40.78

50 Day Range

MA: $46.00

$39.06

$51.84

2 Week Range

Now: $40.66

$22.35

$53.27

Volume

1,145,939 shs

Average Volume

582,401 shs

Market Capitalization

$2.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.16

Is Starlink Set For The Largest IPO In History?

From Paradigm Press | Ad

Click here now for the urgent details.